How to Use Your R&D Tax Refund as a Capital Strategy, Not Just a Compliance Exercise

By Alex Knight, Founder and CEO, Advanced

Every year we talk to founders who are sitting on a cashflow problem that isn't actually a cashflow problem.

They're spending seriously on eligible R&D. Their adviser has lodged prior claims. The refund is coming. But they're managing payroll timing, deferring a hire, or considering a bridge round, all because the ATO won't process their claim until October.

That's a timing problem dressed as a capital problem. And the way you solve it changes everything about how the financial year plays out.

This is a guide to using the R&D Tax Incentive as an active capital strategy. Not as a compliance task that produces a payment at the end. As something you plan around, deploy early, and use to compound the next refund before the year closes.

What most founders do with their R&D refund (and what they miss)

The standard approach goes like this: register with AusIndustry, engage an R&D tax adviser, lodge the claim after 30 June, wait. The refund arrives in October or November. It goes into the operating account and gets absorbed into the business.

That's not wrong. It captures the benefit. But it treats the refund as a passive receivable rather than an active capital tool. The founders who get more from the program understand one thing the others don't: the timing of when capital reaches your account, relative to 30 June, changes what you can do with it. Capital before 30 June can go back into eligible R&D before the financial year closes. That reinvested spend generates its own refundable offset at 43.5%. You're using money you've already earned to earn more. Capital after 30 June belongs to next year's cycle.

That's the whole mechanic. Everything in this article is an elaboration of that one idea.

The R&D Tax Incentive cashflow strategy: how it actually works

The R&D Tax Incentive pays back 43.5 cents for every dollar of eligible R&D expenditure to Australian companies with aggregated annual turnover under $20 million. The refund is a cash payment from the ATO, not a tax deduction, which means it's available to pre-revenue companies and loss-making startups.

The gap between when you spend and when you receive sits at 9 to 12 months. You spend across the financial year, lodge the claim after 30 June, and the ATO processes it over the following months. R&D financing closes that gap. A facility is structured against your anticipated refund. The lender advances a percentage of what's coming before the ATO processes it. When the refund arrives, it repays the facility in a single payment. No monthly repayments, no equity, no personal guarantees.

Here's where strategy comes in.

If you access your anticipated refund early enough in the financial year, you can reinvest a portion back into eligible R&D activity before 30 June. That additional spend generates its own refundable offset. A company with a $300,000 anticipated refund that accesses $261,000 early and reinvests $200,000 into eligible R&D before the year closes increases its next anticipated refund by $87,000.

Same program. Same activities. Bigger refund next year, because the capital arrived in time to be put back to work.

The three places this changes the outcome

1. Runway that doesn't require equity

A company with 10 months of runway and a $261,000 anticipated refund isn't actually operating on 10 months of runway. That refund is a committed receivable. The government has structured a program to pay it. When you include it in your runway calculation as a monthly accrual, the picture shifts. At $600,000 in eligible annual R&D spend, the anticipated refund is $261,000. Divided across 12 months, that's $21,750 accruing per month. On $800,000 in cash with $80,000 monthly burn, standard runway is 10 months. With the refund accrual factored in, adjusted net burn is $58,250 and runway extends to 13.7 months.

Nearly four months of additional runway without any operational change. When founders access that capital early rather than waiting on the ATO, those months stop being theoretical and become actual cash available for hiring, product, and infrastructure decisions.

For a more detailed walkthrough of how to build this calculation and how to present it to your board, see our startup runway calculation guide for Australian founders.

2. Compounding the refund before 30 June

This is the one most founders don't model. And it's worth modelling. The capital flywheel runs on one rule: every dollar of eligible R&D spend before 30 June generates 43.5 cents in anticipated refund. So when you access your refund early and put it back into eligible activity before the year closes, you're generating additional refund on top of refund.

The numbers on a $300,000 anticipated refund accessed at full value: reinvest $200,000 into eligible R&D before 30 June, generate an additional $87,000 in anticipated refund for next year. That $87,000 is then accessible early through R&D financing, and the cycle runs again. This isn't a loophole. The RDTI was designed to reward companies genuinely investing in experimental work. Accessing the refund early and reinvesting it into more experimental work is exactly what the program exists to support.

3. Managing the Payday Super window from July 2026

From 1 July 2026, super contributions move from quarterly to every payday. The float most businesses have been using to manage working capital disappears.

For companies with teams and serious R&D spend, this creates a specific problem: outgoings increase on 1 July, but the R&D refund doesn't arrive until October. That's a four-month window where the cashflow position is tighter than it's been in previous years, and where the buffer of the quarterly super cycle no longer exists.

Founders who access their anticipated refund before 30 June enter that window in a different position. The ones who wait on the ATO go into July without capital they could have had.

For a full breakdown of how Payday Super affects R&D-investing businesses, see our Payday Super cashflow guide.

What this means for advisers and CFOs

If you're advising founders on their R&D Tax Incentive claims, the strategic framing matters more from FY26 than it has in previous years. Two things have changed.

First, the Budget proposed a 10-year cap on the refundable RDTI. Companies incorporated before July 2018 face losing access to the cash refund component from July 2028 under the current proposal. The legislation hasn't passed, but for affected clients, FY26 and FY27 claims are the most valuable they'll ever lodge. Helping them access and deploy the capital efficiently is the highest-value thing an adviser can do for this cohort right now.

Second, most advisers treat the RDTI as a compliance task. The conversation ends when the claim is lodged. But a client who accesses $300,000 early and reinvests $250,000 into eligible R&D before 30 June generates $108,750 in additional anticipated refund. That doesn't appear anywhere in the claim itself. It only appears if the client is planning around the capital, which requires an adviser conversation that goes beyond lodgement timing.

The practical checklist

Before 30 June:

Confirm eligible R&D activities are registered with AusIndustry. Quantify anticipated eligible spend for the year to date. Model the anticipated refund at 43.5% of eligible spend. Calculate what accessing that refund early and reinvesting before 30 June generates in additional anticipated refund next year. If the number is meaningful, compare the cost of R&D financing against the value of that uplift.

When modelling the reinvestment:

Not all spend is eligible. Work with your R&D adviser to identify what portion of planned activity before 30 June qualifies as core or supporting activity under the program definitions. The eligible spend is what generates the offset.

When comparing financing options:

The right comparison isn't R&D financing against doing nothing. It's R&D financing against the next-best option: usually a bridge round at a dilutive valuation. The cost of the financing is a monthly fee on the facility. The cost of a bridge round is permanent equity dilution that stays on the cap table long after the gap it was filling has closed.

For a full comparison of R&D financing against venture debt and other non-dilutive options, see R&D financing vs venture debt.

‍